Skip to main content
Advertising

Originally published Monday, May 7, 2012 at 2:36 PM

  • Share:
             
  • Comments ((0))
  • Print

Summary Box: Hoped-for cholesterol drug scrapped

DRUG KILLED: Roche has ended all testing of experimental drug dalcetrapib, meant to raise good cholesterol, after a late-stage study showed it didn't help patients.

The Associated Press

Comments
No comments have been posted to this article.

advertising

DRUG KILLED: Roche has ended all testing of experimental drug dalcetrapib, meant to raise good cholesterol, after a late-stage study showed it didn't help patients.

CLASS EFFECT?: It's the second cholesterol drug of four in a class called CETP inhibitors to be scrapped. The other, Pfizer's torcetrapib, raised heart risks. They were planned to succeed the lucrative statin drugs, including Lipitor and Crestor.

STILL ON: Merck is continuing a huge, late-stage study of its CETP inhibitor, anacetrapib. Eli Lilly is about to start a late-stage study of its drug, evacetrapib.

News where, when and how you want it

Email Icon

Relive the magic

Relive the magic

Shop for unique souvenirs highlighting great sports moments in Seattle history.

Advertising

Advertising

NDN Video

Advertising